- Home
- AHG vs AUTL Comparison
AHG vs AUTL Comparison
Compare AHG & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHG
- AUTL
- Stock Information
- Founded
- AHG 2013
- AUTL 2014
- Country
- AHG China
- AUTL United Kingdom
- Employees
- AHG N/A
- AUTL N/A
- Industry
- AHG Business Services
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AHG Consumer Discretionary
- AUTL Health Care
- Exchange
- AHG Nasdaq
- AUTL Nasdaq
- Market Cap
- AHG 765.9M
- AUTL 625.4M
- IPO Year
- AHG N/A
- AUTL 2018
- Fundamental
- Price
- AHG $1.78
- AUTL $1.75
- Analyst Decision
- AHG
- AUTL Strong Buy
- Analyst Count
- AHG 0
- AUTL 5
- Target Price
- AHG N/A
- AUTL $9.12
- AVG Volume (30 Days)
- AHG 34.0K
- AUTL 2.7M
- Earning Date
- AHG 09-02-2025
- AUTL 08-12-2025
- Dividend Yield
- AHG N/A
- AUTL N/A
- EPS Growth
- AHG N/A
- AUTL N/A
- EPS
- AHG N/A
- AUTL N/A
- Revenue
- AHG $14,777,798.00
- AUTL $29,934,000.00
- Revenue This Year
- AHG N/A
- AUTL $472.28
- Revenue Next Year
- AHG N/A
- AUTL $114.92
- P/E Ratio
- AHG N/A
- AUTL N/A
- Revenue Growth
- AHG 512.09
- AUTL 185.17
- 52 Week Low
- AHG $0.74
- AUTL $1.11
- 52 Week High
- AHG $2.35
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- AHG 52.90
- AUTL 32.10
- Support Level
- AHG $1.63
- AUTL $1.70
- Resistance Level
- AHG $1.84
- AUTL $1.89
- Average True Range (ATR)
- AHG 0.12
- AUTL 0.15
- MACD
- AHG -0.01
- AUTL -0.06
- Stochastic Oscillator
- AHG 63.68
- AUTL 11.49
About AHG Akso Health Group ADS
Akso Health Group formerly Xiaobai Maimai Inc is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.